“Chronic Pulmonary Aspergillosis: A Threat to Individuals with Lung Diseases and the Challenges of Diagnosis and Treatment with Triazoles in the Presence of Mycobacterial Coinfection”

2023-05-02 07:24:37

People with various lung diseases are at risk of developing chronic pulmonary aspergillosis (CPA), even with a good immune status. This leads to increased morbidity and mortality and represents a significant diagnostic and therapeutic challenge. Drug therapy is carried out with triazoles, which have to be taken over a long period of time. Coinfections with mycobacteria have a particularly unfavorable prognosis.

Jannicke Wiik Nielsen/GettyImages

Chronic pulmonary aspergillosis (CPA) is a rare and problematic lung disease caused by sac fungi of the genus Aspergillus, which can complicate numerous other lung diseases and is associated with high morbidity and mortality. Typical underlying diseases include asthma, sarcoidosis, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) or a chronic granulomatous disease (CGD).

To see the content you need to log in or register.